Tags

Type your tag names separated by a space and hit enter

The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats.
Domest Anim Endocrinol. 2020 Apr 18; 74:106484.DA

Abstract

Somatostatin secretion from islet delta cells is important in maintaining low glycemic variability (GV) by providing negative feedback to beta cells and inhibiting insulin secretion. Capromorelin is a ghrelin-receptor agonist that activates the growth hormone secretagogue receptor on delta cells. We hypothesized that in cats, capromorelin administration will result in decreased GV at the expense of reduced insulin secretion and glucose tolerance. Seven healthy cats were treated with capromorelin from days 1-30. After the first day, fasting blood glucose increased (+13 ± 3 mg/dL, P < 0.0001), insulin decreased (+128 ± 122 ng/dL, P = 0.03), and glucagon was unchanged. Blood glucose was increased throughout an intravenous glucose tolerance test on day 1 with blunting of first-phase insulin response ([FPIR] 4,931 ± 2,597 ng/L/15 min) compared with day -3 (17,437 ± 8,302 ng/L/15 min, P = 0.004). On day 30, FPIR was still blunted (9,993 ± 4,285 ng/L/15 min, P = 0.045), but glucose tolerance returned to baseline. Mean interstitial glucose was increased (+19 ± 6 mg/dL, P = 0.03) on days 2-4 but returned to baseline by days 27-29 (P = 0.3). On days 2-4, GV was increased (SD = 9.7 ± 3.2) compared with baseline (SD = 5.0 ± 1.1, P = 0.02) and returned to baseline on days 27-29 (SD = 6.1 ± 1.1, P = 0.16). In summary, capromorelin caused a decline in insulin secretion and glycemic control and an increase in glucose variability early in the course of treatment, but these effects diminished toward the end of 30 d of treatment.

Authors+Show Affiliations

Department of Veterinary Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA.Department of Veterinary Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA.Department of Veterinary Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA.Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA.Department of Veterinary Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA.Department of Veterinary Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA.Department of Veterinary Medicine and Epidemiology, College of Veterinary Medicine, University of California, Davis, 1 Shields Ave, Davis, CA 95616, USA; Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, 2015 SW 16th Ave, Gainesville, FL 32610, USA. Electronic address: cgilor@ufl.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32619812

Citation

Pires, J, et al. "The Effect of the Ghrelin-receptor Agonist Capromorelin On Glucose Metabolism in Healthy Cats." Domestic Animal Endocrinology, vol. 74, 2020, p. 106484.
Pires J, Greathouse RL, Quach N, et al. The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats. Domest Anim Endocrinol. 2020;74:106484.
Pires, J., Greathouse, R. L., Quach, N., Huising, M. O., Crakes, K. R., Miller, M., & Gilor, C. (2020). The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats. Domestic Animal Endocrinology, 74, 106484. https://doi.org/10.1016/j.domaniend.2020.106484
Pires J, et al. The Effect of the Ghrelin-receptor Agonist Capromorelin On Glucose Metabolism in Healthy Cats. Domest Anim Endocrinol. 2020 Apr 18;74:106484. PubMed PMID: 32619812.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats. AU - Pires,J, AU - Greathouse,R L, AU - Quach,N, AU - Huising,M O, AU - Crakes,K R, AU - Miller,M, AU - Gilor,C, Y1 - 2020/04/18/ PY - 2020/02/10/received PY - 2020/03/24/revised PY - 2020/04/12/accepted PY - 2020/7/4/pubmed PY - 2020/7/4/medline PY - 2020/7/4/entrez KW - Diabetes mellitus KW - Glucagon KW - Growth hormone KW - IGF-1 KW - Insulin SP - 106484 EP - 106484 JF - Domestic animal endocrinology JO - Domest. Anim. Endocrinol. VL - 74 N2 - Somatostatin secretion from islet delta cells is important in maintaining low glycemic variability (GV) by providing negative feedback to beta cells and inhibiting insulin secretion. Capromorelin is a ghrelin-receptor agonist that activates the growth hormone secretagogue receptor on delta cells. We hypothesized that in cats, capromorelin administration will result in decreased GV at the expense of reduced insulin secretion and glucose tolerance. Seven healthy cats were treated with capromorelin from days 1-30. After the first day, fasting blood glucose increased (+13 ± 3 mg/dL, P < 0.0001), insulin decreased (+128 ± 122 ng/dL, P = 0.03), and glucagon was unchanged. Blood glucose was increased throughout an intravenous glucose tolerance test on day 1 with blunting of first-phase insulin response ([FPIR] 4,931 ± 2,597 ng/L/15 min) compared with day -3 (17,437 ± 8,302 ng/L/15 min, P = 0.004). On day 30, FPIR was still blunted (9,993 ± 4,285 ng/L/15 min, P = 0.045), but glucose tolerance returned to baseline. Mean interstitial glucose was increased (+19 ± 6 mg/dL, P = 0.03) on days 2-4 but returned to baseline by days 27-29 (P = 0.3). On days 2-4, GV was increased (SD = 9.7 ± 3.2) compared with baseline (SD = 5.0 ± 1.1, P = 0.02) and returned to baseline on days 27-29 (SD = 6.1 ± 1.1, P = 0.16). In summary, capromorelin caused a decline in insulin secretion and glycemic control and an increase in glucose variability early in the course of treatment, but these effects diminished toward the end of 30 d of treatment. SN - 1879-0054 UR - https://www.unboundmedicine.com/medline/citation/32619812/The_effect_of_the_ghrelin-receptor_agonist_capromorelin_on_glucose_metabolism_in_healthy_cats L2 - https://linkinghub.elsevier.com/retrieve/pii/S0739-7240(20)30051-5 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.